ificant transformation of our International
businesses during our fiscal years 2008 and 2007. This transformation
resulted in the formation of a shared service center in Europe, and exiting
various offices across Europe, and Japan. We have also removed In-Process
research and development expenses associated with the acquisition of Arryx,
Inc. in FY07. Additionally, we removed the receipt of an award resulting
from a net settlement agreement against a competitor in FY07. Lastly
removed is the impact of a reduction to income tax due to the finalization
of an audit of prior year income tax returns in FY07. We believe this
information is useful for investors because it allows for an evaluation of
the Company with a focus on the performance of our core operations.
-- Non-GAAP S,G&A and Non-GAAP Operating Expenses
The use of this non-GAAP measure allows management to monitor the
ongoing level of spend that is necessary to support the business in a
period when we are not transforming our business, or completing an
acquisition of in-process research and development. We establish our
budgets, forecasts, and performance targets excluding these costs.
-- Non-GAAP Operating Income and Non-GAAP Income Before Income Taxes
The use of these non-GAAP measures allows management to monitor the
level of operating and total pre-tax profits without the costs of our
business transformation or in-process research and development costs.
We establish our budgets, forecasts, and performance targets on this
basis.
-- Non-GAAP Operating Income and Non-GAAP Income Before Income Taxes
The use of these non-GAAP measures allows management to monitor the
level of operating and total pre-tax profits without the costs of our
business transformation or in-process research and development costs.
We establish our budgets, forecasts, and performance targ
'/>"/>
SOURCE Haemonetics Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Related medicine news :1.
Haemonetics Webcast Presentation2.
Keiko Hattori Joins Haemonetics as President of Haemonetics Japan3.
Haemonetics Appoints Executive Leadership of European Operations4.
Haemonetics Sets Date for Q3FY08 Earnings Release and Conference Call - January 31, 20085.
Haemonetics(R) Reports Strong Results for Third Quarter Fiscal 2008 with Continued Double Digit Growth in Sales6.
Haemonetics(R) Software Solutions to Launch Application for Workflow Optimization in Blood Collection Centers7.
Haemonetics Sets Date for Fourth Quarter and Fiscal Year End 2008 Earnings Release and Conference Call - May 1, 20088.
New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites9.
Haemacure Reports Third Quarter 2007 Results10.
First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion11.
Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best